Regeneron Pharmaceuticals Inc $ 344.08 0 (0%)
On watch
Volume:
686,211
Avg Vol (1m):
735,791
Market Cap $:
37.78 Bil
Enterprise Value $:
35.61 Bil
P/E (TTM):
18.42
P/B:
3.59
Financial Strength | 8/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 4.04 | ||
| Equity-to-Asset | 0.75 | ||
| Debt-to-Equity | 0.07 | ||
| Debt-to-EBITDA | 0.29 | ||
| Interest Coverage | 72.89 | ||
| Piotroski F-Score | 5 | ||
| Altman Z-Score | 8.8 | ||
| Beneish M-Score | -2.26 | ||
| WACC vs ROIC | |||
Profitability Rank | 8/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 29.55 | ||
| Net Margin % | 28.13 | ||
| ROE % | 23.14 | ||
| ROA % | 17.15 | ||
| ROC (Joel Greenblatt) % | 46.06 | ||
| 3-Year Revenue Growth Rate | 18 | ||
| 3-Year EBITDA Growth Rate | 27.8 | ||
| 3-Year EPS without NRI Growth Rate | 56.8 |
Valuation Rank | 10/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 18.42 | ||
| Forward PE Ratio | 13.42 | ||
| PE Ratio without NRI | 18.42 | ||
| Price-to-Owner-Earnings | 29.1 | ||
| PB Ratio | 3.59 | ||
| PS Ratio | 5.18 | ||
| Price-to-Free-Cash-Flow | 19.82 | ||
| Price-to-Operating-Cash-Flow | 16.67 | ||
| EV-to-EBIT | 15.85 | ||
| EV-to-EBITDA | 14.56 | ||
| EV-to-Revenue | 4.67 | ||
| PEG Ratio | 0.63 | ||
| Shiller PE Ratio | 50.18 | ||
| Current Ratio | 4.03 | ||
| Quick Ratio | 3.27 | ||
| Days Inventory | 655.12 | ||
| Days Sales Outstanding | 127.39 | ||
| Days Payable | 181.37 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.4 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 3.59 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 1.61 | ||
| Price-to-Median-PS-Value | 0.53 | ||
| Price-to-Peter-Lynch-Fair-Value | 0.73 | ||
| Price-to-Graham-Number | 1.71 | ||
| Earnings Yield (Greenblatt) % | 6.31 | ||
| Forward Rate of Return (Yacktman) % | 22.87 |